Johnson & Johnson Cash on Hand 2010-2022 | JNJ

Johnson & Johnson cash on hand from 2010 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
  • Johnson & Johnson cash on hand for the quarter ending December 31, 2022 was $34.079B, a 9.93% increase year-over-year.
  • Johnson & Johnson cash on hand for 2021 was $31.608B, a 25.5% increase from 2020.
  • Johnson & Johnson cash on hand for 2020 was $25.185B, a 30.58% increase from 2019.
  • Johnson & Johnson cash on hand for 2019 was $19.287B, a 2.03% decline from 2018.
Johnson & Johnson Annual Cash on Hand
(Millions of US $)
2021 $31,608
2020 $25,185
2019 $19,287
2018 $19,687
2017 $18,296
2016 $41,907
2015 $38,376
2014 $33,089
2013 $29,206
2012 $21,089
2011 $32,261
2010 $27,658
2009 $19,425
Johnson & Johnson Quarterly Cash on Hand
(Millions of US $)
2022-09-30 $34,079
2022-06-30 $32,568
2022-03-31 $30,388
2021-12-31 $31,608
2021-09-30 $31,001
2021-06-30 $25,306
2021-03-31 $24,619
2020-12-31 $25,185
2020-09-30 $30,781
2020-06-30 $19,135
2020-03-31 $18,024
2019-12-31 $19,287
2019-09-30 $17,945
2019-06-30 $15,278
2019-03-31 $15,336
2018-12-31 $19,687
2018-09-30 $19,364
2018-06-30 $18,139
2018-03-31 $15,204
2017-12-31 $18,296
2017-09-30 $16,231
2017-06-30 $12,853
2017-03-31 $39,343
2016-12-31 $41,907
2016-09-30 $40,433
2016-06-30 $42,584
2016-03-31 $39,855
2015-12-31 $38,376
2015-09-30 $37,306
2015-06-30 $33,954
2015-03-31 $31,319
2014-12-31 $33,089
2014-09-30 $33,005
2014-06-30 $31,624
2014-03-31 $29,392
2013-12-31 $29,206
2013-09-30 $25,228
2013-06-30 $25,129
2013-03-31 $21,668
2012-12-31 $21,089
2012-09-30 $19,771
2012-06-30 $16,915
2012-03-31 $33,847
2011-12-31 $32,261
2011-09-30 $30,927
2011-06-30 $29,682
2011-03-31 $26,867
2010-12-31 $27,658
2010-09-30 $22,126
2010-06-30 $18,901
2010-03-31 $18,010
2009-12-31 $19,425
2009-09-30 $14,337
2009-06-30 $14,716
2009-03-31 $13,933
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $432.802B $94.943B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $314.224B 41.65
Novo Nordisk (NVO) Denmark $299.481B 38.14
Merck (MRK) United States $262.312B 13.83
AbbVie (ABBV) United States $256.147B 10.62
Pfizer (PFE) United States $248.894B 6.74
Novartis AG (NVS) Switzerland $190.505B 14.09